https://news.medxy.ai/zh/energy-needs-assessment/Medxy AIzh2026-11-04T04:34:42-08:00精确评估能量需求：专为精英自行车运动员量身打造的新静息代谢率方程 https://news.medxy.ai/ja/energy-needs-assessment-sports/Medxy AIja2026-11-04T04:34:23-08:00エネルギー需要の正確な評価：エリート自転車選手向けに最適化された、新たな安静時代謝率推定式 https://news.medxy.ai/vi/resting-metabolic-rate-equation/Medxy AIvi2026-11-04T04:34:00-08:00Đánh giá năng lượng chính xác hơn: Phương trình tốc độ chuyển hóa lúc nghỉ mới dành riêng cho vận động viên đua xe đạp đẳng cấp cao https://news.medxy.ai/precision-in-energy-assessment-a-new-resting-metabolic-rate-equation-tailored-for-elite-cyclists/Medxy AIen2026-11-04T04:33:44-08:00Precision in Energy Assessment: A New Resting Metabolic Rate Equation Tailored for Elite Cyclists https://news.medxy.ai/zh/high-dose-botox-spasticity/Medxy AIzh2026-11-04T04:33:04-08:00高剂量 onabotulinumtoxinA 治疗肢体痉挛的安全性与有效性：一项前瞻性观察性研究 https://news.medxy.ai/ja/high-dose-onabotulinumtoxina-for-spasticity/Medxy AIja2026-11-04T04:32:49-08:00四肢痙縮に対する高用量 onabotulinumtoxinA の安全性と有効性：前向き観察研究 https://news.medxy.ai/vi/high-dose-onabotulinumtoxina-spasticity/Medxy AIvi2026-11-04T04:32:29-08:00Đánh giá tính an toàn và hiệu quả của onabotulinumtoxinA liều cao trong điều trị co cứng chi: Nghiên cứu quan sát tiến cứu https://news.medxy.ai/safety-and-effectiveness-of-high-dose-onabotulinumtoxina-for-limb-spasticity-a-prospective-observational-study/Medxy AIen2026-11-04T04:32:12-08:00Safety and Effectiveness of High-Dose OnabotulinumtoxinA for Limb Spasticity: A Prospective Observational Study https://news.medxy.ai/zh/postoperative-dental-pain-mobile-health-ndprn/Medxy AIzh2026-11-04T04:31:30-08:00解读牙科术后疼痛：基于“国家牙科临床实践研究网络”（National Dental Practice-Based Research Network）利用移动医疗得出的研究发现 https://news.medxy.ai/ja/postoperative-dental-pain-mobile-health/Medxy AIja2026-11-04T04:31:09-08:00歯科処置後の術後疼痛を読み解く：モバイルヘルスを活用したNational Dental Practice-Based Research Networkの知見 https://news.medxy.ai/vi/dental-procedure-pain/Medxy AIvi2026-11-04T04:30:44-08:00Đau sau thủ thuật nha khoa: Những hiểu biết từ Mạng lưới Nghiên cứu Dựa trên Thực hành Nha khoa Quốc gia qua nền tảng y tế di động https://news.medxy.ai/postoperative-pain-after-dental-procedures-insights-from-the-national-dental-practice-based-research-network-using-a-mobile-health-platform/Medxy AIen2026-11-04T04:30:27-08:00Postoperative Pain After Dental Procedures: Insights from the National Dental Practice-Based Research Network Using a Mobile Health Platform https://news.medxy.ai/zh/sacituzumab-endometrial-cancer/Medxy AIzh2026-11-04T04:29:36-08:00Sacituzumab Tirumotecan在既往治疗后子宫内膜癌中的优效性：TroFuse-005Ⅲ期试验改写治疗格局 https://news.medxy.ai/ja/sacituzumab-tirumotecan-endometrial-cancer/Medxy AIja2026-11-04T04:29:14-08:00既治療子宮内膜癌におけるサシツズマブ・ティルモテカンが有望：TroFuse-005第3相試験が治療戦略を前進 https://news.medxy.ai/vi/sacituzumab-tirumotecan-endometrial-cancer-2/Medxy AIvi2026-11-04T04:28:43-08:00Sacituzumab tirumotecan vượt trội hơn lựa chọn của bác sĩ trong ung thư nội mạc tử cung đã điều trị trước: thử nghiệm pha 3 TroFuse-005 mở ra bước tiến mới trong điều trị https://news.medxy.ai/dual-remission-of-atopic-dermatitis-and-frequently-relapsing-nephrotic-syndrome-with-dupilumab/Medxy AIen2026-11-04T04:27:18-08:00Dual Remission of Atopic Dermatitis and Frequently Relapsing Nephrotic Syndrome With Dupilumab https://news.medxy.ai/ja/polymyalgia-imaging-guidelines/Medxy AIja2026-11-04T04:26:38-08:00多発性筋痛症の画像診断はいつ・どう行うべきか：標的を絞ったエビデンス重視の国際推奨 https://news.medxy.ai/vi/polymyalgia-rheumatica-imaging-guidelines/Medxy AIvi2026-11-04T04:26:07-08:00Khi nào và chụp hình ảnh như thế nào trong polymyalgia rheumatica: khuyến nghị quốc tế cho cách tiếp cận có mục tiêu, dựa trên bằng chứng https://news.medxy.ai/zh/polymyalgia-rheumatica-imaging-recommendations/Medxy AIzh2026-11-04T04:25:35-08:00多发性肌痛风湿病何时、如何做影像学检查：面向靶向、循证策略的国际建议 https://news.medxy.ai/when-and-how-to-image-polymyalgia-rheumatica-international-recommendations-for-a-targeted-evidence-based-approach/Medxy AIen2026-11-04T04:25:09-08:00When and How to Image Polymyalgia Rheumatica: International Recommendations for a Targeted, Evidence-Based Approach https://news.medxy.ai/zh/glp-1-heart-transplant-diabetes/Medxy AIzh2026-11-04T04:24:04-08:00GLP-1受体激动剂在心脏移植后糖尿病管理中的疗效与安全性：来自西班牙多中心研究的启示 https://news.medxy.ai/vi/glp-1-after-heart-transplant/Medxy AIvi2026-11-04T04:23:22-08:00Chất chủ vận thụ thể GLP-1 trong kiểm soát đái tháo đường sau ghép ở người nhận ghép tim: bằng chứng từ một nghiên cứu đa trung tâm tại Tây Ban Nha https://news.medxy.ai/efficacy-and-safety-of-glp-1-receptor-agonists-in-managing-post-transplant-diabetes-among-heart-transplant-patients-insights-from-a-multicenter-spanish-study/Medxy AIen2026-11-04T04:23:02-08:00Efficacy and Safety of GLP-1 Receptor Agonists in Managing Post-Transplant Diabetes Among Heart Transplant Patients: Insights from a Multicenter Spanish Study https://news.medxy.ai/zh/identifying-secondary-syphilis/Medxy AIzh2026-11-04T04:22:13-08:00如何识别二期梅毒：扁平湿疣的临床与组织病理学要点 https://news.medxy.ai/ja/secondary-syphilis-signs/Medxy AIja2026-11-04T04:21:53-08:00二期梅毒をどう見抜くか：扁平コンジローマの臨床・組織病理学的ポイント https://news.medxy.ai/vi/reliably-identifying-secondary-syphilis/Medxy AIvi2026-11-04T04:21:29-08:00Khi giang mai giai đoạn hai có thể nhận diện một cách đáng tin cậy: Những hiểu biết lâm sàng và mô bệnh học về condyloma lata https://news.medxy.ai/when-secondary-syphilis-is-reliably-recognizable-clinical-and-histopathologic-insights-into-condyloma-lata/Medxy AIen2026-11-04T04:21:10-08:00When Secondary Syphilis is Reliably Recognizable: Clinical and Histopathologic Insights into Condyloma Lata https://news.medxy.ai/zh/patient-specific-virtual-planning/Medxy AIzh2026-11-04T04:20:19-08:00患者特异性虚拟规划提升创伤后眼眶-颧骨重建的对称性与心理社会结局 https://news.medxy.ai/ja/patient-specific-reconstruction-planning/Medxy AIja2026-11-04T04:20:00-08:00患者特異的仮想計画で高める、外傷後眼窩頬骨上顎複合体再建の対称性と心理社会的転帰 https://news.medxy.ai/vi/personalized-orbital-zygomatic-reconstruction/Medxy AIvi2026-11-04T04:19:33-08:00Cải thiện đối xứng và kết cục tâm lý–xã hội trong tái tạo phức hợp ổ mắt–gò má sau chấn thương bằng lập kế hoạch ảo cá thể hóa https://news.medxy.ai/enhanced-symmetry-and-psychosocial-outcomes-in-post-traumatic-orbital-zygomatic-complex-reconstruction-using-patient-specific-virtual-planning/Medxy AIen2026-11-04T04:19:12-08:00Enhanced Symmetry and Psychosocial Outcomes in Post-Traumatic Orbital Zygomatic Complex Reconstruction Using Patient-Specific Virtual Planning https://news.medxy.ai/zh/cluster-vs-individual-randomization/Medxy AIzh2026-11-04T04:18:18-08:00簇随机还是个体随机？急性救治试验中的效应估计差异解析 https://news.medxy.ai/ja/cluster-vs-individual-randomization-2/Medxy AIja2026-11-04T04:17:56-08:00クラスター無作為化か、それとも個体無作為化か？――急性期治療試験における効果推定値の差異に関する分析 https://news.medxy.ai/vi/cluster-randomized-trials/Medxy AIvi2026-11-04T04:17:33-08:00Ngẫu nhiên hóa theo cụm hay theo cá thể trong thử nghiệm chăm sóc cấp tính? Phân tích từ một nghiên cứu meta-dịch tễ học https://news.medxy.ai/evaluating-cluster-vs-individual-randomization-in-acute-care-trials-insights-from-a-meta-epidemiological-study/Medxy AIen2026-11-04T04:17:12-08:00Evaluating Cluster vs. Individual Randomization in Acute Care Trials: Insights from a Meta-Epidemiological Study https://news.medxy.ai/zh/anticoagulation-in-elderly-atrial-fibrillation/Medxy AIzh2026-11-04T04:16:30-08:00高龄房颤患者抗凝治疗：死亡获益与出血风险如何权衡 https://news.medxy.ai/ja/anticoagulation-elderly-afib/Medxy AIja2026-11-04T04:16:11-08:0080代心房細動患者における抗凝固療法：死亡抑制と出血リスクのバランス https://news.medxy.ai/vi/anticoagulation-in-octogenarians/Medxy AIvi2026-11-04T04:15:52-08:00Điều trị chống đông ở bệnh nhân rung nhĩ tuổi bát tuần: Cân bằng giữa lợi ích sống còn và nguy cơ chảy máu https://news.medxy.ai/anticoagulation-in-octogenarians-with-atrial-fibrillation-balancing-mortality-benefits-and-bleeding-risks/Medxy AIen2026-11-04T04:15:36-08:00Anticoagulation in Octogenarians with Atrial Fibrillation: Balancing Mortality Benefits and Bleeding Risks https://news.medxy.ai/zh/adult-autoimmune-neutropenia-therapy/Medxy AIzh2026-11-04T04:14:28-08:00成人自身免疫性中性粒细胞减少症：诊断与个体化治疗策略 https://news.medxy.ai/ja/adult-autoimmune-neutropenia/Medxy AIja2026-11-04T04:14:13-08:00成人自己免疫性好中球減少症を読み解く：診断と個別化治療の要点 https://news.medxy.ai/vi/autoimmune-neutropenia-adults/Medxy AIvi2026-11-04T04:13:53-08:00Giảm bạch cầu trung tính tự miễn ở người lớn: chẩn đoán và chiến lược điều trị cá thể hóa https://news.medxy.ai/navigating-autoimmune-neutropenia-in-adults-diagnosis-and-tailored-treatment-strategies/Medxy AIen2026-11-04T04:13:39-08:00Navigating Autoimmune Neutropenia in Adults: Diagnosis and Tailored Treatment Strategies https://news.medxy.ai/zh/mild-moderate-copd-phenotypes-prognosis/Medxy AIzh2026-11-04T04:12:59-08:00揭示轻至中度COPD：来自社区队列研究的独特表型与不同预后 https://news.medxy.ai/ja/mild-moderate-copd-phenotypes/Medxy AIja2026-11-04T04:12:39-08:00軽症から中等症COPDを読み解く：地域コホート研究が示した多様な表現型と予後の違い https://news.medxy.ai/unraveling-mild-to-moderate-copd-distinct-phenotypes-and-prognostic-diversity-from-a-community-cohort-study/Medxy AIen2026-11-04T04:12:02-08:00Unraveling Mild-to-Moderate COPD: Distinct Phenotypes and Prognostic Diversity from a Community Cohort Study https://news.medxy.ai/zh/lens-capsule-spacer-technique/Medxy AIzh2026-11-04T04:11:20-08:00自体前晶状体囊作为巩膜内间隔物：提升深层巩膜切除术疗效的新策略 https://news.medxy.ai/ja/lens-capsule-spacer-technique-improving-deep-sclerectomy-results/Medxy AIja2026-11-04T04:11:04-08:00強膜内スペーサーとしての自己前水晶体嚢：深層強膜切除術の治療成績を向上させる新たな戦略 https://news.medxy.ai/vi/improving-deep-sclerectomy-results/Medxy AIvi2026-11-04T04:10:42-08:00Nâng cao kết quả phẫu thuật củng mạc sâu: Bao trước thủy tinh thể tự thân như một miếng đệm trong củng mạc hiệu quả https://news.medxy.ai/enhancing-deep-sclerectomy-outcomes-autologous-anterior-lens-capsule-as-an-effective-intrascleral-spacer/Medxy AIen2026-11-04T04:10:25-08:00Enhancing Deep Sclerectomy Outcomes: Autologous Anterior Lens Capsule as an Effective Intrascleral Spacer https://news.medxy.ai/zh/targeting-engrailed-1-fibroblasts/Medxy AIzh2026-11-04T04:09:44-08:00靶向 Engrailed-1 成纤维细胞：抑制 YAP/TAZ 通路治疗特发性声门下狭窄的新策略 https://news.medxy.ai/ja/targeting-fibroblasts-for-stenosis/Medxy AIja2026-11-04T04:09:19-08:00YAP/TAZ阻害によるEngrailed-1線維芽細胞の標的化：特発性声門下狭窄に対する新規治療戦略 https://news.medxy.ai/vi/targeting-fibroblasts-in-airway-stenosis/Medxy AIvi2026-11-04T04:08:57-08:00Nhắm trúng đích các nguyên bào sợi Engrailed-1 qua ức chế con đường YAP/TAZ: chiến lược điều trị mới cho hẹp dưới thanh môn vô căn https://news.medxy.ai/zh/recover-days-at-home-after-gastrosurgery/Medxy AIzh2026-11-04T04:07:47-08:00胃肠癌术后居家天数：一项以患者为中心的结局指标的评估 https://news.medxy.ai/ja/days-at-home-after-gastrosurgery/Medxy AIja2026-11-04T04:07:27-08:00消化器がん手術後の在宅日数：患者中心の転帰指標の検討 https://news.medxy.ai/vi/days-at-home-after-surgery/Medxy AIvi2026-11-04T04:07:00-08:00Số ngày ở nhà sau phẫu thuật ung thư đường tiêu hóa: Thẩm định một chỉ số kết cục lấy người bệnh làm trung tâm https://news.medxy.ai/days-at-home-after-gastrointestinal-cancer-surgery-validating-a-patient-centered-outcome-metric/Medxy AIen2026-11-04T04:06:40-08:00Days at Home After Gastrointestinal Cancer Surgery: Validating a Patient-Centered Outcome Metric https://news.medxy.ai/zh/us-fetal-newborn-hemolytic-disease-burden/Medxy AIzh2026-11-04T04:05:38-08:00美国重度胎儿及新生儿溶血病全国负担估算 https://news.medxy.ai/ja/estimating-national-impact-hemolytic-disease/Medxy AIja2026-11-04T04:05:12-08:00米国における重症胎児・新生児溶血性疾患の全国的影響を推定する https://news.medxy.ai/vi/national-fetal-anemia-impact/Medxy AIvi2026-11-04T04:04:49-08:00Ước tính tác động toàn quốc của bệnh tan máu nặng ở thai nhi và trẻ sơ sinh tại Hoa Kỳ https://news.medxy.ai/estimating-the-national-impact-of-severe-hemolytic-disease-of-the-fetus-and-newborn-in-the-united-states/Medxy AIen2026-11-04T04:04:32-08:00Estimating the National Impact of Severe Hemolytic Disease of the Fetus and Newborn in the United States https://news.medxy.ai/zh/derazantinib-cholangiocarcinoma/Medxy AIzh2026-11-04T04:03:54-08:00FGFR2 异常肝内胆管癌中的 Derazantinib：II 期疗效可观，毒性可控 https://news.medxy.ai/ja/darasatinib-cholangiocarcinoma/Medxy AIja2026-11-04T04:03:35-08:00FGFR2異常を有する肝内胆管癌に対するダラザンチニブ：管理可能な毒性を伴う有望な第2相有効性 https://news.medxy.ai/vi/derazantinib-cholangiocarcinoma-research/Medxy AIvi2026-11-04T04:03:13-08:00Derazantinib trong ung thư đường mật trong gan có biến đổi FGFR2: Hiệu quả đầy hứa hẹn ở pha 2 với độc tính có thể kiểm soát https://news.medxy.ai/derazantinib-in-fgfr2-altered-intrahepatic-cholangiocarcinoma-promising-phase-2-efficacy-with-manageable-toxicity/Medxy AIen2026-11-04T04:02:55-08:00Derazantinib in FGFR2-Altered Intrahepatic Cholangiocarcinoma: Promising Phase 2 Efficacy with Manageable Toxicity https://news.medxy.ai/zh/spinal-demyelinating-leukodystrophy/Medxy AIzh2026-11-04T04:02:08-08:00揭示 SPDMLS：PLAAT4 功能获得性变异与以脊髓为主的脱髓鞘性白质营养不良 https://news.medxy.ai/ja/unraveling-spdmls-plaati4-mutation/Medxy AIja2026-11-04T04:01:50-08:00SPDMLSの正体を解く：脊髄優位脱髄性白質ジストロフィーにおけるPLAAT4機能獲得型変異 https://news.medxy.ai/vi/spdmls-plaat4-variants-myelin-disorder/Medxy AIvi2026-11-04T04:01:30-08:00Khám phá SPDMLS: Các biến thể PLAAT4 tăng chức năng trong loạn dưỡng chất trắng mất myelin ưu thế tủy sống https://news.medxy.ai/unraveling-spdmls-gain-of-function-plaat4-variants-in-spinal-predominant-demyelinating-leukodystrophy/Medxy AIen2026-11-04T04:01:14-08:00Unraveling SPDMLS: Gain-of-Function PLAAT4 Variants in Spinal Predominant Demyelinating Leukodystrophy https://news.medxy.ai/zh/acmopatide-type-1-diabetes/Medxy AIzh2026-11-04T04:00:30-08:00Acmopatide 在超重 1 型糖尿病成人中显示出良好的控糖与减重前景：Ⅱ期试验结果 https://news.medxy.ai/ja/promising-diabetes-treatment-results/Medxy AIja2026-11-04T04:00:12-08:001型糖尿病の過体重成人で有望な血糖・体重管理効果　acmopatide第2相試験の結果 https://news.medxy.ai/vi/acmopatide-trial-results/Medxy AIvi2026-11-04T03:59:51-08:00Acmopatide cho thấy triển vọng kiểm soát đường huyết và cân nặng ở người lớn thừa cân mắc đái tháo đường type 1: Kết quả thử nghiệm giai đoạn 2 https://news.medxy.ai/acmopatide-shows-promising-glycemic-and-weight-control-in-overweight-adults-with-type-1-diabetes-phase-2-trial-results/Medxy AIen2026-11-04T03:59:34-08:00Acmopatide Shows Promising Glycemic and Weight Control in Overweight Adults with Type 1 Diabetes: Phase 2 Trial Results https://news.medxy.ai/zh/hlhs-prognosis-study/Medxy AIzh2026-11-04T03:58:46-08:00HLHS不同亚型及心室-冠状动脉连接对预后的影响：Fetal Heart Society多中心研究新发现 https://news.medxy.ai/ja/hlhs-outcomes-hypoplastic-left-heart-syndrome/Medxy AIja2026-11-04T03:58:26-08:00HLHSの亜型および心室－冠動脈連結が予後に及ぼす影響：Fetal Heart Societyによる多施設共同研究の新たな知見 https://news.medxy.ai/vi/outcomes-hypoplastic-left-heart-syndrome/Medxy AIvi2026-11-04T03:58:05-08:00Nối thất – vành và các phân nhóm trong hội chứng tim trái giảm sản: phát hiện từ nghiên cứu đa trung tâm của Fetal Heart Society https://news.medxy.ai/impact-of-subtypes-and-ventriculocoronary-connections-on-hypoplastic-left-heart-syndrome-outcomes-insights-from-the-fetal-heart-society-multicenter-study/Medxy AIen2026-11-04T03:57:47-08:00Impact of Subtypes and Ventriculocoronary Connections on Hypoplastic Left Heart Syndrome Outcomes: Insights from the Fetal Heart Society Multicenter Study https://news.medxy.ai/zh/platelet-plasma-knee-trial/Medxy AIzh2026-11-04T03:56:59-08:00优化早期膝骨关节炎的富血小板血浆治疗：标准化临床路径的多中心随机试验 https://news.medxy.ai/ja/optimizing-prp-for-early-knee-osteoarthritis/Medxy AIja2026-11-04T03:56:38-08:00早期膝変形性関節症におけるPRP療法を最適化する：標準化臨床パスウェイの多施設ランダム化試験 https://news.medxy.ai/vi/standardized-prp-therapy-knee-osteoarthritis/Medxy AIvi2026-11-04T03:56:15-08:00Tối ưu hóa liệu pháp huyết tương giàu tiểu cầu trong thoái hóa khớp gối giai đoạn sớm: thử nghiệm ngẫu nhiên đa trung tâm về một quy trình lâm sàng chuẩn hóa https://news.medxy.ai/optimizing-platelet-rich-plasma-therapy-in-early-knee-osteoarthritis-a-multicenter-randomized-trial-of-a-standardized-clinical-pathway/Medxy AIen2026-11-04T03:55:55-08:00Optimizing Platelet-Rich Plasma Therapy in Early Knee Osteoarthritis: A Multicenter Randomized Trial of a Standardized Clinical Pathway https://news.medxy.ai/zh/oral-health-priorities/Medxy AIzh2026-11-04T03:54:59-08:00重新审视依赖照护老年人的口腔健康优先事项：来自多方利益相关者视角的启示 https://news.medxy.ai/ja/rethinking-oral-healthcare/Medxy AIja2026-11-04T03:54:40-08:00依存度の高い高齢者の口腔保健を再考する――多様なステークホルダーの視点から見えた課題 https://news.medxy.ai/vi/oral-health-priorities-elderly-dependent/Medxy AIvi2026-11-04T03:54:20-08:00Đặt lại ưu tiên sức khỏe răng miệng cho người cao tuổi phụ thuộc: Góc nhìn từ nhiều bên liên quan https://news.medxy.ai/reevaluating-oral-health-priorities-for-dependent-older-adults-insights-from-multi-stakeholder-perspectives/Medxy AIen2026-11-04T03:54:06-08:00Reevaluating Oral Health Priorities for Dependent Older Adults: Insights from Multi-Stakeholder Perspectives https://news.medxy.ai/ja/tarlatamab-durvalumab-maintenance-therapy/Medxy AIja2026-11-04T03:53:02-08:00進展型小細胞肺癌の維持療法におけるタルラタマブ＋デュルバルマブ：生存転帰を大きく改善する新展開 https://news.medxy.ai/vi/tarlatamab-durvalumab-small-cell-lung-cancer-survival/Medxy AIvi2026-11-04T03:52:42-08:00Tarlatamab phối hợp Durvalumab trong điều trị duy trì ung thư phổi tế bào nhỏ giai đoạn lan rộng: Bước tiến nổi bật về sống còn https://news.medxy.ai/tarlatamab-plus-durvalumab-as-maintenance-therapy-in-extensive-stage-small-cell-lung-cancer-a-breakthrough-in-survival-outcomes/Medxy AIen2026-11-04T03:52:24-08:00Tarlatamab Plus Durvalumab as Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer: A Breakthrough in Survival Outcomes https://news.medxy.ai/zh/exercise-and-cognition/Medxy AIzh2026-11-03T03:25:35-08:00运动如何为中年女性认知“护航”：领域特异性效应与运动方式差异的新发现 https://news.medxy.ai/ja/exercise-and-cognition-2/Medxy AIja2026-11-03T03:25:17-08:00中年期女性の認知機能を支える運動の力：領域別効果と運動様式の違い https://news.medxy.ai/vi/exercise-as-cognitive-buffer/Medxy AIvi2026-11-03T03:24:55-08:00Tập luyện như một “bộ đệm” nhận thức ở phụ nữ trung niên: tác động theo lĩnh vực và khác biệt giữa các hình thức tập luyện https://news.medxy.ai/exercise-as-a-cognitive-buffer-in-midlife-women-insights-into-domain-specific-effects-and-modality-differences/Medxy AIen2026-11-03T03:24:37-08:00Exercise as a Cognitive Buffer in Midlife Women: Insights into Domain-Specific Effects and Modality Differences https://news.medxy.ai/zh/safer-mobility-parkinsons-fall-prevention/Medxy AIzh2026-11-03T03:23:52-08:00赋能更安全的移动行为：预防帕金森病跌倒的临床与研究启示 https://news.medxy.ai/ja/empowering-safer-mobility/Medxy AIja2026-11-03T03:23:29-08:00パーキンソン病の転倒予防へ：より安全な移動行動を支えるエンパワーメントとは https://news.medxy.ai/vi/safer-mobility-fall-prevention/Medxy AIvi2026-11-03T03:23:07-08:00Trao quyền để tăng cường vận động an toàn hơn nhằm phòng ngừa ngã ở bệnh Parkinson: Góc nhìn từ bác sĩ lâm sàng và nhà nghiên cứu https://news.medxy.ai/safer-mobility-parkinsons/Medxy AIen2026-11-03T03:22:49-08:00Empowering Safer Mobility Behaviors to Prevent Falls in Parkinson’s Disease: Insights from Clinicians and Researchers https://news.medxy.ai/zh/eating-difficulty-warning-signs/Medxy AIzh2026-11-03T03:22:10-08:00进食困难：老年人功能脆弱与认知下降的警示信号——来自四个大型老龄化队列的证据 https://news.medxy.ai/ja/eating-difficulties-in-aging/Medxy AIja2026-11-03T03:21:53-08:00高齢者の摂食困難は何を示すのか――4つの大規模高齢化コホートからみた機能的脆弱性と認知低下のサイン https://news.medxy.ai/vi/eating-difficulties-in-older-adults/Medxy AIvi2026-11-03T03:21:27-08:00Khó khăn ăn uống như một dấu ấn của tình trạng dễ tổn thương chức năng rộng hơn và suy giảm nhận thức ở người cao tuổi: Bằng chứng từ 4 đoàn hệ già hóa quy mô lớn https://news.medxy.ai/eating-difficulty-as-a-marker-for-broader-functional-vulnerability-and-cognitive-decline-in-older-adults-insights-from-four-large-ageing-cohorts/Medxy AIen2026-11-03T03:21:08-08:00Eating Difficulty as a Marker for Broader Functional Vulnerability and Cognitive Decline in Older Adults: Insights from Four Large Ageing Cohorts https://news.medxy.ai/zh/egfr-nsclc-breakthrough/Medxy AIzh2026-11-03T03:20:23-08:00EGFR 突变晚期 NSCLC 新突破：Izalontamab Brengitecan 优于含铂化疗 https://news.medxy.ai/ja/izarontamab-brenzitecan-egfr-nsclc/Medxy AIja2026-11-03T03:19:57-08:00EGFR変異陽性NSCLCにおけるイザロントマブ ブレンジテカン、第3世代EGFR TKI後のプラチナ化学療法を上回る可能性 https://news.medxy.ai/vi/izalontamab-brengitecan-nsclc/Medxy AIvi2026-11-03T03:19:35-08:00Izalontamab Brengitecan cho thấy hiệu quả đầy hứa hẹn hơn hóa trị platinum ở NSCLC đột biến EGFR sau tiến triển với EGFR TKI thế hệ ba https://news.medxy.ai/izalontamab-brengitecan-shows-promising-efficacy-over-platinum-chemotherapy-in-egfr-mutated-nsclc-post-third-generation-egfr-tki-progression/Medxy AIen2026-11-03T03:19:16-08:00Izalontamab Brengitecan Shows Promising Efficacy Over Platinum Chemotherapy in EGFR-Mutated NSCLC Post-Third-Generation EGFR TKI Progression https://news.medxy.ai/zh/executive-function-in-preterm-children/Medxy AIzh2026-11-03T03:11:26-08:00极早产儿童执行功能的纵向发展：青春期仍存持续挑战 https://news.medxy.ai/ja/executive-function-in-preterm-infants/Medxy AIja2026-11-03T03:11:07-08:00超早産児の実行機能の縦断的発達：思春期においても続く課題 https://news.medxy.ai/vi/executive-function-preterm-infants/Medxy AIvi2026-11-03T03:10:45-08:00Chức năng điều hành ở trẻ sinh cực non tháng: thách thức kéo dài đến tuổi vị thành niên https://news.medxy.ai/longitudinal-executive-function-development-in-very-preterm-children-persistent-challenges-into-adolescence/Medxy AIen2026-11-03T03:10:25-08:00Longitudinal Executive Function Development in Very Preterm Children: Persistent Challenges into Adolescence https://news.medxy.ai/zh/ccl20-macrophages-axial-spondyloarthritis/Medxy AIzh2026-11-03T03:09:39-08:00揭示 CCL20+ 巨噬细胞在中轴型脊柱关节炎滑膜中作为 TNF 产生者的作用：靶向治疗的新启示 https://news.medxy.ai/ja/tnf-producing-macrophages-in-axspa-synovium/Medxy AIja2026-11-03T03:09:21-08:00AxSpA滑膜におけるCCL20+マクロファージのTNF産生能を解明：標的治療への示唆 https://news.medxy.ai/vi/ccl20-macrophages-axial-spondyloarthritis-2/Medxy AIvi2026-11-03T03:08:52-08:00Đại thực bào CCL20+ trong synovium viêm cột sống dính khớp trục: nguồn sản xuất TNF và ý nghĩa đối với điều trị nhắm đích https://news.medxy.ai/unveiling-the-role-of-ccl20-macrophages-as-tnf-producers-in-axial-spondyloarthritis-synovium-implications-for-targeted-therapy/Medxy AIen2026-11-03T03:08:32-08:00Unveiling the Role of CCL20+ Macrophages as TNF Producers in Axial Spondyloarthritis Synovium: Implications for Targeted Therapy https://news.medxy.ai/zh/serum-lrg-1-citrulline-ratio/Medxy AIzh2026-11-03T03:07:51-08:00血清LRG-1与瓜氨酸比值：用于肠移植排斥监测的突破性生物标志物组合 https://news.medxy.ai/ja/serum-lrg-1-citrulline-ratio-2/Medxy AIja2026-11-03T03:07:32-08:00血清LRG-1とシトルリン比が切り拓く、腸移植拒絶反応モニタリングの新規バイオマーカーペア https://news.medxy.ai/vi/lrg-1-citrulline-transplant-rejection/Medxy AIvi2026-11-03T03:07:03-08:00LRG-1 huyết thanh và tỷ lệ citrulline: Cặp dấu ấn sinh học đột phá trong theo dõi thải ghép sau ghép ruột https://news.medxy.ai/serum-lrg-1-and-citrulline-ratio-a-breakthrough-biomarker-duo-for-intestinal-transplant-rejection-monitoring/Medxy AIen2026-11-03T03:06:45-08:00Serum LRG-1 and Citrulline Ratio: A Breakthrough Biomarker Duo for Intestinal Transplant Rejection Monitoring https://news.medxy.ai/zh/infantile-hemangioma-ulceration/Medxy AIzh2026-11-03T03:05:54-08:00口服普萘洛尔治疗后婴幼儿血管瘤溃疡：大样本回顾性研究揭示的风险因素与临床特征 https://news.medxy.ai/ja/infantile-hemangioma-ulceration-2/Medxy AIja2026-11-03T03:05:23-08:00経口プロプラノロール治療後の乳児血管腫潰瘍化：大規模後ろ向き研究からみた危険因子と臨床像 https://news.medxy.ai/vi/ulceration-risk-after-propranolol/Medxy AIvi2026-11-03T03:05:00-08:00Nguy cơ loét u máu trẻ em sau điều trị propranolol đường uống: Phát hiện từ một nghiên cứu hồi cứu quy mô lớn https://news.medxy.ai/risk-factors-and-clinical-profile-of-infantile-hemangioma-ulceration-post-oral-propranolol-treatment-insights-from-a-large-retrospective-study/Medxy AIen2026-11-03T03:04:42-08:00Risk Factors and Clinical Profile of Infantile Hemangioma Ulceration Post Oral Propranolol Treatment: Insights from a Large Retrospective Study https://news.medxy.ai/zh/citrate-growth-factor-treatment/Medxy AIzh2026-11-03T03:03:59-08:00枸橼酸钠优化浓缩生长因子治疗：兼顾舒适度与疗效的雄激素性脱发新策略 https://news.medxy.ai/ja/androgenic-alopecia-treatment/Medxy AIja2026-11-03T03:03:33-08:00男性型脱毛症治療を前進させる：クエン酸ナトリウムが濃縮成長因子療法の快適性と有効性を高める https://news.medxy.ai/vi/hair-loss-treatment-breakthrough/Medxy AIvi2026-11-03T03:03:12-08:00Đột phá trong điều trị rụng tóc: natri citrat giúp tăng sự thoải mái và hiệu quả của liệu pháp yếu tố tăng trưởng cô đặc ở rụng tóc nội tiết tố nam https://news.medxy.ai/advancing-hair-loss-therapy-sodium-citrate-enhances-comfort-and-efficacy-of-concentrated-growth-factor-treatment-in-androgenetic-alopecia/Medxy AIen2026-11-03T03:02:53-08:00Advancing Hair Loss Therapy: Sodium Citrate Enhances Comfort and Efficacy of Concentrated Growth Factor Treatment in Androgenetic Alopecia https://news.medxy.ai/zh/mitochondrial-dysfunction-sepsis/Medxy AIzh2026-11-03T03:02:14-08:00脓毒症中的线粒体失能与血小板过度激活：一种新的治疗靶点 https://news.medxy.ai/ja/platelet-mitochondrial-dysfunction-sepsis/Medxy AIja2026-11-03T03:01:52-08:00敗血症における血小板過剰活性化とミトコンドリア機能障害：新たな治療標的 https://news.medxy.ai/vi/mitochondrial-dysfunction-in-sepsis/Medxy AIvi2026-11-03T03:01:32-08:00Rối loạn chức năng ty thể và tăng hoạt hóa tiểu cầu: Đích điều trị mới trong nhiễm khuẩn huyết https://news.medxy.ai/mitochondrial-dysfunction-and-platelet-hyperactivation-a-novel-therapeutic-target-in-sepsis/Medxy AIen2026-11-03T03:01:08-08:00Mitochondrial Dysfunction and Platelet Hyperactivation: A Novel Therapeutic Target in Sepsis https://news.medxy.ai/zh/cardiovascular-risk-prediction/Medxy AIzh2026-11-03T03:00:24-08:00绝经后慢性肾脏病女性的心血管风险预测：来自 Women’s Health Initiative 的研究启示 https://news.medxy.ai/ja/cardiovascular-risk-prediction-in-ckd/Medxy AIja2026-11-03T03:00:06-08:00閉経後慢性腎臓病女性における心血管リスク予測：Women’s Health Initiative（女性の健康イニシアチブ）からの知見 https://news.medxy.ai/vi/cardiovascular-risk-prediction-2/Medxy AIvi2026-11-03T02:59:46-08:00Đánh giá các mô hình dự đoán nguy cơ tim mạch ở phụ nữ sau mãn kinh mắc bệnh thận mạn tính: Bằng chứng từ Women’s Health Initiative https://news.medxy.ai/assessing-cardiovascular-risk-prediction-models-in-postmenopausal-women-with-chronic-kidney-disease-insights-from-the-womens-health-initiative/Medxy AIen2026-11-03T02:59:28-08:00Assessing Cardiovascular Risk Prediction Models in Postmenopausal Women With Chronic Kidney Disease: Insights from the Women’s Health Initiative https://news.medxy.ai/zh/donor-derived-malignancy-epidemiology/Medxy AIzh2026-11-03T02:58:48-08:00西班牙移植中心揭示供者细胞来源血液肿瘤：DDHN 的流行病学与分子基础 https://news.medxy.ai/vi/donor-derived-hematologic-neoplasms/Medxy AIvi2026-11-03T02:58:04-08:00Giải mã u tân sinh huyết học có nguồn gốc từ tế bào người cho: Góc nhìn từ các trung tâm ghép của Tây Ban Nha https://news.medxy.ai/unraveling-donor-cell-derived-hematologic-neoplasms-insights-from-spanish-transplant-centers/Medxy AIen2026-11-03T02:57:46-08:00Unraveling Donor Cell-Derived Hematologic Neoplasms: Insights from Spanish Transplant Centers https://news.medxy.ai/zh/targeting-macrophage-axis/Medxy AIzh2026-11-03T02:57:07-08:00靶向巨噬细胞YTHDC1/TIGAR/NF-κB轴：治疗肺动脉高压的新策略 https://news.medxy.ai/ja/targeting-macrophage-thdc1-tigar-axis/Medxy AIja2026-11-03T02:56:50-08:00マクロファージのYTHDC1/TIGAR/NF-κB軸を標的とする：肺動脈性肺高血圧症治療の新たな戦略 https://news.medxy.ai/vi/targeting-pulmonary-hypertension/Medxy AIvi2026-11-03T02:56:29-08:00Nhắm đích trục YTHDC1/TIGAR/NF-κB ở đại thực bào: chiến lược điều trị mới cho tăng áp phổi https://news.medxy.ai/pulmonary-hypertension-treatment/Medxy AIen2026-11-03T02:56:11-08:00Targeting the Macrophage YTHDC1/TIGAR/NF-κB Axis: A Novel Therapeutic Strategy for Pulmonary Hypertension https://news.medxy.ai/zh/uci-cystinosis-crystal-score-validation/Medxy AIzh2026-11-03T02:55:26-08:00UCI角膜胱氨酸晶体评分的临床验证：连接胱氨酸贮积症中的客观影像与症状负担 https://news.medxy.ai/ja/uci-corneal-crystal-score-validation/Medxy AIja2026-11-03T02:55:06-08:00UCI角膜シスチン結晶スコアの臨床的妥当性を検証：シスチノーシスにおける画像所見と症状負荷を結ぶ https://news.medxy.ai/vi/clinical-corneal-assessment/Medxy AIvi2026-11-03T02:54:45-08:00Thẩm định lâm sàng thang điểm UCI CCCS của giác mạc: Kết nối hình ảnh khách quan với gánh nặng triệu chứng trong cystinosis https://news.medxy.ai/clinical-validation-of-the-uci-corneal-cystine-crystal-score-linking-objective-imaging-and-symptom-burden-in-cystinosis/Medxy AIen2026-11-03T02:54:25-08:00Clinical Validation of the UCI Corneal Cystine Crystal Score: Linking Objective Imaging and Symptom Burden in Cystinosis https://news.medxy.ai/zh/psychosocial-stress-vocal-fold-epithelium/Medxy AIzh2026-11-03T02:53:41-08:00心理社会应激如何影响声带上皮：来自无菌与常规饲养小鼠的启示 https://news.medxy.ai/ja/psychosocial-stress-vocal-folds/Medxy AIja2026-11-03T02:53:23-08:00心理社会的ストレスは声帯上皮にどう影響するのか：無菌マウスと通常飼育マウスからみた新知見 https://news.medxy.ai/vi/psychosocial-stress-impact-on-vocal-fold-epithelium/Medxy AIvi2026-11-03T02:53:01-08:00Căng thẳng tâm lý – xã hội ảnh hưởng như thế nào đến biểu mô dây thanh? https://news.medxy.ai/exploring-the-impact-of-psychosocial-stress-on-vocal-fold-epithelium-insights-from-germ-free-and-conventionally-raised-mice/Medxy AIen2026-11-03T02:52:45-08:00Exploring the Impact of Psychosocial Stress on Vocal Fold Epithelium: Insights from Germ-Free and Conventionally-Raised Mice https://news.medxy.ai/zh/slow-transit-constipation-surgery/Medxy AIzh2026-11-03T02:50:33-08:00慢传输性便秘手术治疗：次全结肠切除术与全结肠切除术孰优？STOPS随机临床试验解读 https://news.medxy.ai/ja/subtotal-vs-total-colectomy-constipation/Medxy AIja2026-11-03T02:50:09-08:00難治性遅延性通過性便秘に対する亜全結腸切除術と全結腸切除術の比較：STOPS無作為化臨床試験からの知見 https://news.medxy.ai/vi/partial-vs-total-colectomy-constipation/Medxy AIvi2026-11-03T02:49:46-08:00Cắt đại tràng bán phần hay toàn bộ: phương án nào hiệu quả hơn cho táo bón vận chuyển chậm? Kết quả từ thử nghiệm STOPS https://news.medxy.ai/comparative-efficacy-of-subtotal-versus-total-colectomy-for-slow-transit-constipation-insights-from-the-stops-randomized-clinical-trial/Medxy AIen2026-11-03T02:49:26-08:00Comparative Efficacy of Subtotal Versus Total Colectomy for Slow-Transit Constipation: Insights from the STOPS Randomized Clinical Trial https://news.medxy.ai/zh/leep-lugol-staining-trial/Medxy AIzh2026-11-03T02:48:38-08:00LEEP 术中卢戈尔碘染色：随机试验证实其常规应用并不理想 https://news.medxy.ai/ja/iodine-staining-leep-necessity/Medxy AIja2026-11-03T02:48:13-08:00LEEP中の術中ヨウ素染色は必要か？　ランダム化試験が routine 使用に疑問を投げかける https://news.medxy.ai/vi/iodine-staining-leep-trial/Medxy AIvi2026-11-03T02:47:54-08:00Nhuộm i-ốt trong mổ khi thực hiện LEEP: Thử nghiệm ngẫu nhiên đặt câu hỏi về việc dùng thường quy https://news.medxy.ai/intraoperative-iodine-staining-during-leep-a-randomized-trial-challenging-its-routine-use/Medxy AIen2026-11-03T02:47:37-08:00Intraoperative Iodine Staining During LEEP: A Randomized Trial Challenging Its Routine Use https://news.medxy.ai/zh/diet-reduces-crohns-inflammation/Medxy AIzh2026-11-03T02:46:58-08:00饮食干预可减轻克罗恩病高风险亲属的肠道炎症：PIONIR试验带来新启示 https://news.medxy.ai/ja/dietary-crohns-prevention/Medxy AIja2026-11-03T02:46:37-08:00高リスク家族における腸管炎症を食事で抑制　PIONIR試験が示したクローン病一次予防の可能性 https://news.medxy.ai/vi/nutrition-reduces-crohns-risk/Medxy AIvi2026-11-03T02:46:16-08:00Can thiệp dinh dưỡng giúp giảm viêm ruột ở thân nhân nguy cơ cao của bệnh nhân Crohn: Góc nhìn từ thử nghiệm PIONIR https://news.medxy.ai/dietary-intervention-lowers-intestinal-inflammation-in-high-risk-relatives-of-crohns-disease-patients-insights-from-the-pionir-trial/Medxy AIen2026-11-03T02:45:57-08:00Dietary Intervention Lowers Intestinal Inflammation in High-Risk Relatives of Crohn’s Disease Patients: Insights from the PIONIR Trial https://news.medxy.ai/zh/self-guided-internet-therapy-functional-seizures/Medxy AIzh2026-11-03T02:45:16-08:00自主式互联网治疗显著减少功能性发作：来自随机临床试验的启示 https://news.medxy.ai/ja/self-guided-internet-therapy-seizures/Medxy AIja2026-11-03T02:44:57-08:00自己主導型のインターネット治療が機能性発作を有意に減少させる：ランダム化臨床試験からの示唆 https://news.medxy.ai/vi/internet-guided-seizure-treatment/Medxy AIvi2026-11-03T02:44:30-08:00Can thiệp qua internet tự hướng dẫn giúp giảm rõ rệt cơn co giật chức năng: góc nhìn từ một thử nghiệm lâm sàng ngẫu nhiên https://news.medxy.ai/self-guided-internet-based-therapy-significantly-reduces-functional-seizures-insights-from-a-randomized-clinical-trial/Medxy AIen2026-11-03T02:44:10-08:00Self-Guided Internet-Based Therapy Significantly Reduces Functional Seizures: Insights from a Randomized Clinical Trial https://news.medxy.ai/zh/semaglutide-vs-glp1-drugs-dialysis-diabetes/Medxy AIzh2026-11-03T02:43:32-08:00血液透析糖尿病患者中司美格鲁肽与度拉糖肽或利拉鲁肽：比较疗效更优 https://news.medxy.ai/ja/semaglutide-vs-other-glp1-drugs/Medxy AIja2026-11-03T02:43:13-08:00血液透析を受ける糖尿病患者におけるセマグルチドとデュラグルチド／リラグルチドの比較有効性 https://news.medxy.ai/vi/semaglutide-vs-dulaglutide-liraglutide/Medxy AIvi2026-11-03T02:42:51-08:00Semaglutide vượt trội ra sao so với dulaglutide hoặc liraglutide ở bệnh nhân đái tháo đường đang lọc máu? https://news.medxy.ai/comparative-effectiveness-of-semaglutide-versus-dulaglutide-or-liraglutide-in-hemodialysis-patients-with-diabetes/Medxy AIen2026-11-03T02:42:34-08:00Comparative Effectiveness of Semaglutide versus Dulaglutide or Liraglutide in Hemodialysis Patients with Diabetes https://news.medxy.ai/zh/slowing-coronary-calcification-dancode-vitk2/Medxy AIzh2026-11-03T02:41:54-08:00延缓冠状动脉钙化进展：来自DANCODE试验关于补充维生素K2和D3的启示 https://news.medxy.ai/ja/slowing-coronary-calcification-dancode/Medxy AIja2026-11-03T02:41:36-08:00冠動脈石灰化の進行を遅らせる：ビタミンK2およびD3の補充に関するDANCODE試験からの考察 https://news.medxy.ai/vi/slowing-coronary-calcification/Medxy AIvi2026-11-03T02:41:14-08:00Làm chậm tiến triển vôi hóa động mạch vành: Góc nhìn từ thử nghiệm DANCODE về bổ sung vitamin K2 và D3 https://news.medxy.ai/modulating-coronary-artery-calcification-progression-insights-from-the-dancode-trial-on-vitamin-k2-and-d3-supplementation/Medxy AIen2026-11-03T02:40:55-08:00Modulating Coronary Artery Calcification Progression: Insights from the DANCODE Trial on Vitamin K2 and D3 Supplementation https://news.medxy.ai/zh/glenohumeral-track-concept/Medxy AIzh2026-11-03T02:40:10-08:00前方肩关节不稳定合并盂肱骨缺损中全轨迹概念的评估：对临床决策的启示 https://news.medxy.ai/ja/glenohumeral-track-concept-2/Medxy AIja2026-11-03T02:39:50-08:00前方肩関節不安定症および関節窩・上腕骨欠損を伴う症例における「全軌跡（フル・トラジェクトリー）」概念の評価 https://news.medxy.ai/vi/glenohumeral-track-concept-1/Medxy AIvi2026-11-03T02:39:28-08:00Đánh giá khái niệm “Full-Track” trong tình trạng mất vững khớp vai ra trước kèm theo các khuyết hổng xương ổ chảo – cánh tay https://news.medxy.ai/zh/post-stroke-rehabilitation-comparison/Medxy AIzh2026-11-03T02:39:12-08:00急性卒中后康复效果如何？住院康复机构与专业护理机构的比较 https://news.medxy.ai/evaluating-the-global-track-concept-in-anterior-shoulder-instability-with-glenohumeral-bone-loss-implications-for-clinical-decision-making/Medxy AIen2026-11-03T02:39:10-08:00Evaluating the Global Track Concept in Anterior Shoulder Instability with Glenohumeral Bone Loss: Implications for Clinical Decision-Making https://news.medxy.ai/ja/post-stroke-rehabilitation-outcomes/Medxy AIja2026-11-03T02:38:51-08:00急性期脳卒中後のリハビリ転帰を比較：入院リハビリテーション施設と熟練看護施設の違い https://news.medxy.ai/vi/rehabilitation-outcomes-acute-stroke/Medxy AIvi2026-11-03T02:38:28-08:00Đánh giá kết quả phục hồi chức năng: So sánh cơ sở nội trú và cơ sở điều dưỡng chuyên môn sau đột quỵ cấp https://news.medxy.ai/evaluating-rehabilitation-outcomes-inpatient-rehabilitation-facilities-versus-skilled-nursing-facilities-post-acute-stroke/Medxy AIen2026-11-03T02:38:11-08:00Evaluating Rehabilitation Outcomes: Inpatient Rehabilitation Facilities Versus Skilled Nursing Facilities Post-Acute Stroke https://news.medxy.ai/zh/oral-rinse-recovery/Medxy AIzh2026-11-03T02:37:34-08:00口腔冲洗有助于口腔癌重建后微生物组稳定与恢复 https://news.medxy.ai/ja/oral-rinse-microbiome-stability/Medxy AIja2026-11-03T02:37:16-08:00口腔洗浄でマイクロバイオームは安定化するのか――口腔がん再建術後の回復を支える可能性 https://news.medxy.ai/vi/oral-rinse-recovery-2/Medxy AIvi2026-11-03T02:36:51-08:00Tưới rửa miệng giúp ổn định hệ vi sinh và thúc đẩy hồi phục sau tái tạo ung thư khoang miệng https://news.medxy.ai/oral-irrigation-enhances-microbiome-stability-and-recovery-after-oral-cancer-reconstruction/Medxy AIen2026-11-03T02:36:31-08:00Oral Irrigation Enhances Microbiome Stability and Recovery After Oral Cancer Reconstruction https://news.medxy.ai/zh/divarasib-kras-g12c-review/Medxy AIzh2026-11-03T02:35:51-08:00KRAS G12C 突变 NSCLC 中 Divarasib 与 Sotorasib、Adagrasib 的比较：临床与转化医学综合综述 https://news.medxy.ai/ja/divarasib-kras-g12c-nsclc-review/Medxy AIja2026-11-03T02:35:26-08:00KRAS G12C変異NSCLCにおけるDivarasibの位置づけ：Sotorasib・Adagrasibとの比較からみる包括的臨床・トランスレーショナルレビュー https://news.medxy.ai/vi/divarasib-vs-sotorasib-adagrasib-krg12c-nsclc/Medxy AIvi2026-11-03T02:34:56-08:00Divarasib so với Sotorasib và Adagrasib trong NSCLC đột biến KRAS G12C: Tổng quan lâm sàng và chuyển dịch toàn diện https://news.medxy.ai/divarasib-compared-with-sotorasib-and-adagrasib-in-kras-g12c-mutated-nsclc-a-comprehensive-clinical-and-translational-review/Medxy AIen2026-11-03T02:34:31-08:00Divarasib Compared with Sotorasib and Adagrasib in KRAS G12C-Mutated NSCLC: A Comprehensive Clinical and Translational Review https://news.medxy.ai/ja/ehealth-exercise-covid-recovery/Medxy AIja2026-11-02T05:25:17-08:00eHealth指導型運動でCOVID-19回復後の最大酸素摂取量と生活の質が改善：ランダム化比較試験 https://news.medxy.ai/vi/ehealth-training-improves-post-covid-outcomes/Medxy AIvi2026-11-02T05:24:59-08:00Tập luyện theo hướng dẫn eHealth giúp tăng mức hấp thu oxy đỉnh và cải thiện chất lượng sống sau COVID-19: Thử nghiệm ngẫu nhiên có đối chứng https://news.medxy.ai/zh/early-mobilization-radial-head-fracture/Medxy AIzh2026-11-02T05:24:06-08:00桡骨头骨折早期控制性活动可促进恢复，且无显著临床差异 https://news.medxy.ai/ja/early-mobilization-radial-head-fractures/Medxy AIja2026-11-02T05:23:46-08:00橈骨頭骨折における早期制御下可動化は、臨床的に有意な差を伴わず回復を促進する https://news.medxy.ai/vi/controlled-early-mobilization-reduces-recovery-time/Medxy AIvi2026-11-02T05:23:23-08:00Huy động sớm có kiểm soát trong gãy đầu quay giúp phục hồi tốt hơn mà không tạo khác biệt lâm sàng đáng kể https://news.medxy.ai/early-controlled-mobilisation-in-radial-head-fractures-enhances-recovery-without-clinically-significant-differences/Medxy AIen2026-11-02T05:23:07-08:00Early Controlled Mobilisation in Radial Head Fractures Enhances Recovery Without Clinically Significant Differences https://news.medxy.ai/zh/dual-action-antibacterial-resin-cement/Medxy AIzh2026-11-02T05:22:27-08:00兼具双重抗菌机制的创新型聚氨酯树脂黏固剂：强化继发龋预防的新策略 https://news.medxy.ai/ja/advanced-antibacterial-cement/Medxy AIja2026-11-02T05:22:09-08:00二次う蝕予防を強化する、二重の抗菌機構を備えた新規ポリウレタンレジンセメント https://news.medxy.ai/vi/polyurethane-antibacterial-cement/Medxy AIvi2026-11-02T05:21:46-08:00Xi măng nhựa polyurethane thế hệ mới với hai cơ chế kháng khuẩn: tiềm năng vượt trội trong phòng ngừa sâu răng thứ phát https://news.medxy.ai/innovative-polyurethane-resin-cement-with-dual-antibacterial-mechanisms-for-enhanced-secondary-caries-prevention/Medxy AIen2026-11-02T05:21:26-08:00Innovative Polyurethane Resin Cement with Dual Antibacterial Mechanisms for Enhanced Secondary Caries Prevention https://news.medxy.ai/zh/remibrutinib-outperforms-teriflunomide/Medxy AIzh2026-11-02T05:20:45-08:00复发型多发性硬化治疗再添新证据：REMODEL-1 与 REMODEL-2 Ⅲ期试验显示 remibrutinib 优于 teriflunomide https://news.medxy.ai/ja/remibrutinib-outperforms-teriflunomide-relm/Medxy AIja2026-11-02T05:20:30-08:00再発型多発性硬化症でremibrutinibがteriflunomideを上回る：REMODEL-1／REMODEL-2第3相試験から見えた有効性と安全性 https://news.medxy.ai/vi/remibrutinib-outperforms-teriflunomide-2/Medxy AIvi2026-11-02T05:20:12-08:00Remibrutinib vượt trội hơn teriflunomide về hiệu quả và độ an toàn trong đa xơ cứng tái phát: Kết quả từ các thử nghiệm pha 3 REMODEL-1 và REMODEL-2 https://news.medxy.ai/remibrutinib-demonstrates-superior-efficacy-and-safety-over-teriflunomide-in-relapsing-multiple-sclerosis-insights-from-remodel-1-and-remodel-2-phase-3-trials/Medxy AIen2026-11-02T05:19:54-08:00Remibrutinib Demonstrates Superior Efficacy and Safety over Teriflunomide in Relapsing Multiple Sclerosis: Insights from REMODEL-1 and REMODEL-2 Phase 3 Trials https://news.medxy.ai/ja/standardizing-pediatric-advocacy-education/Medxy AIja2026-11-02T05:19:15-08:00小児科GMEにおける擁護教育を標準化する新枠組み：Community Pediatrics & Advocacy Curriculum https://news.medxy.ai/vi/community-pediatrics-advocacy-education/Medxy AIvi2026-11-02T05:18:43-08:00Khung Chương trình Nhi khoa Cộng đồng & Biện hộ: Chuẩn hóa giáo dục biện hộ trong đào tạo sau đại học ngành nhi khoa https://news.medxy.ai/zh/community-pediatrics-advocacy-training/Medxy AIzh2026-11-02T05:18:09-08:00社区儿科与倡导课程：儿科研究生医学教育中倡导教育的标准化 https://news.medxy.ai/the-community-pediatrics-advocacy-curriculum-standardizing-advocacy-education-in-pediatric-graduate-medical-education/Medxy AIen2026-11-02T05:17:44-08:00The Community Pediatrics & Advocacy Curriculum: Standardizing Advocacy Education in Pediatric Graduate Medical Education https://news.medxy.ai/zh/early-rheumatoid-arthritis-follow-up/Medxy AIzh2026-11-02T05:16:34-08:00早期类风湿关节炎十年随访：以治疗目标为导向治疗的持久获益与长期成功 https://news.medxy.ai/ja/long-term-ra-remission/Medxy AIja2026-11-02T05:16:19-08:00寛解を10年先へつなぐ：早期関節リウマチにおけるT2T療法の長期成績 https://news.medxy.ai/vi/sustained-remission-rheumatoid-arthritis/Medxy AIvi2026-11-02T05:16:00-08:00Lui bệnh bền vững và thành công lâu dài: Một thập kỷ điều trị theo mục tiêu ở viêm khớp dạng thấp giai đoạn sớm https://news.medxy.ai/sustained-remission-and-long-term-success-a-decade-of-treat-to-target-therapy-in-early-rheumatoid-arthritis/Medxy AIen2026-11-02T05:15:42-08:00Sustained Remission and Long-Term Success: A Decade of Treat-to-Target Therapy in Early Rheumatoid Arthritis https://news.medxy.ai/zh/impact-of-kidney-allocation-reform-3/Medxy AIzh2026-11-02T05:14:38-08:00肾脏分配政策改革及捐献医院地理位置对脑死亡捐献者肾脏利用的影响 https://news.medxy.ai/ja/impact-of-kidney-allocation-reform-2/Medxy AIja2026-11-02T05:14:19-08:00脳死ドナーからの腎臓利用に対する、腎臓配分政策の改革およびドナー提供病院の地理的位置の影響 https://news.medxy.ai/vi/impact-of-kidney-allocation-reform/Medxy AIvi2026-11-02T05:13:54-08:00Tác động của cải cách chính sách phân bổ thận và vị trí địa lý của bệnh viện người hiến đối với việc sử dụng thận từ người hiến đã chết não https://news.medxy.ai/impact-of-kidney-allocation-policy-reforms-and-donor-hospital-geography-on-utilization-of-deceased-donor-kidneys/Medxy AIen2026-11-02T05:13:35-08:00Impact of Kidney Allocation Policy Reforms and Donor Hospital Geography on Utilization of Deceased Donor Kidneys https://news.medxy.ai/zh/biologics-psoriasis-pregnancy/Medxy AIzh2026-11-02T05:12:44-08:00妊娠期银屑病患者使用生物制剂安全吗？一项大型队列研究带来的新证据 https://news.medxy.ai/ja/biologic-treatment-safety-in-pregnancy/Medxy AIja2026-11-02T05:12:28-08:00乾癬妊婦における生物学的治療の安全性：大規模コホート研究からみえた知見 https://news.medxy.ai/vi/biologic-therapy-psoriasis-pregnancy/Medxy AIvi2026-11-02T05:12:08-08:00Liệu pháp sinh học trong thai kỳ ở bệnh vảy nến: Những dữ liệu mới từ một nghiên cứu đoàn hệ quy mô lớn https://news.medxy.ai/safety-of-biologic-therapy-in-pregnancy-for-psoriasis-patients-insights-from-a-large-cohort-study/Medxy AIen2026-11-02T05:11:51-08:00Safety of Biologic Therapy in Pregnancy for Psoriasis Patients: Insights from a Large Cohort Study https://news.medxy.ai/zh/advanced-hemostasis-network-3/Medxy AIzh2026-11-02T05:11:15-08:00植入式止血网片可显著减少面部提升术后的血肿：561例病例分析 https://news.medxy.ai/ja/advanced-hemostasis-network-2/Medxy AIja2026-11-02T05:10:23-08:00フェイスリフト術後の血腫を大幅に低減する先進的な内部止血メッシュ：561症例の分析 https://news.medxy.ai/vi/advanced-hemostasis-network/Medxy AIvi2026-11-02T05:10:05-08:00Mạng cầm máu nội bộ tiên tiến giúp giảm mạnh tụ máu sau phẫu thuật căng da mặt: Phân tích 561 ca https://news.medxy.ai/innovative-internal-hemostatic-network-dramatically-reduces-postoperative-hematoma-after-facelift-surgery-analysis-of-561-cases/Medxy AIen2026-11-02T05:09:48-08:00Innovative Internal Hemostatic Network Dramatically Reduces Postoperative Hematoma After Facelift Surgery: Analysis of 561 Cases https://news.medxy.ai/zh/reducing-pediatric-intubation-cardiac-arrest/Medxy AIzh2026-11-02T05:09:06-08:00降低儿科气管插管中的心搏骤停：来自国家急诊气道注册数据库的启示 https://news.medxy.ai/ja/reducing-pediatric-intubation-arrests/Medxy AIja2026-11-02T05:08:46-08:00小児気管挿管中の心停止を減らすには：National Emergency Airway Registryが示す知見 https://news.medxy.ai/vi/reducing-pediatric-intubation-cardiac-arrests/Medxy AIvi2026-11-02T05:08:22-08:00Giảm ngừng tim trong lúc đặt nội khí quản ở trẻ em: Góc nhìn từ National Emergency Airway Registry https://news.medxy.ai/reducing-cardiac-arrest-during-pediatric-tracheal-intubation-insights-from-the-national-emergency-airway-registry/Medxy AIen2026-11-02T05:08:05-08:00Reducing Cardiac Arrest during Pediatric Tracheal Intubation: Insights from the National Emergency Airway Registry https://news.medxy.ai/zh/medicare-primary-care-billing/Medxy AIzh2026-11-02T05:07:24-08:00Medicare高级初级保健管理计费：阻碍与机遇，早期采用情况解析 https://news.medxy.ai/ja/why-apcm-adoption-stalls/Medxy AIja2026-11-02T05:07:07-08:00MedicareのAPCM請求はなぜ広がらないのか——初年度導入の障壁と可能性 https://news.medxy.ai/vi/medicare-primary-care-payment-adoption/Medxy AIvi2026-11-02T05:06:46-08:00Rào cản và cơ hội trong thanh toán Quản lý Chăm sóc Ban đầu Nâng cao của Medicare: những tín hiệu sớm về mức độ áp dụng https://news.medxy.ai/barriers-and-opportunities-in-medicare-advanced-primary-care-management-billing-early-uptake-insights/Medxy AIen2026-11-02T05:06:29-08:00Barriers and Opportunities in Medicare Advanced Primary Care Management Billing: Early Uptake Insights https://news.medxy.ai/zh/hydroxyurea-stroke-prevention/Medxy AIzh2026-11-02T05:05:51-08:00镰状细胞病卒中预防中羟基脲固定低剂量与中剂量的长期结局：SPRINT队列研究解读 https://news.medxy.ai/ja/long-term-hydroxyurea-outcomes/Medxy AIja2026-11-02T05:05:34-08:00鎌状赤血球症の脳卒中予防におけるhydroxyurea固定低用量と固定中等用量の長期成績：SPRINTコホートからの知見 https://news.medxy.ai/vi/hydroxyurea-dose-stroke-prevention/Medxy AIvi2026-11-02T05:05:15-08:00Hydroxyurea liều cố định thấp hay trung bình: Kết cục dài hạn trong dự phòng đột quỵ ở bệnh hồng cầu hình liềm từ đoàn hệ SPRINT https://news.medxy.ai/long-term-outcomes-of-fixed-low-versus-moderate-hydroxyurea-dosing-in-sickle-cell-stroke-prevention-insights-from-the-sprint-cohort/Medxy AIen2026-11-02T05:04:58-08:00Long-Term Outcomes of Fixed Low versus Moderate Hydroxyurea Dosing in Sickle Cell Stroke Prevention: Insights from the SPRINT Cohort https://news.medxy.ai/redefining-success-in-chronic-cough-treatment-patient-centered-criteria-for-cough-control/Medxy AIen2026-11-02T05:04:23-08:00Redefining Success in Chronic Cough Treatment: Patient-Centered Criteria for Cough Control https://news.medxy.ai/zh/morgagnian-cataract-surgery/Medxy AIzh2026-11-02T05:03:44-08:00Morgagnian白内障：晚期晶状体病变的临床难点与手术结局 https://news.medxy.ai/ja/morgagnian-cataract-surgery-3/Medxy AIja2026-11-02T05:03:24-08:00Morgagnian白内障：進行白内障における臨床的課題と手術成績 https://news.medxy.ai/vi/morgagnian-cataract-surgery-2/Medxy AIvi2026-11-02T05:03:03-08:00Đục thủy tinh thể Morgagnian: Thách thức lâm sàng và kết quả phẫu thuật trong bệnh lý thủy tinh thể tiến triển https://news.medxy.ai/morgagnian-cataracts-clinical-challenges-and-surgical-outcomes-in-advanced-lens-pathology/Medxy AIen2026-11-02T05:02:46-08:00Morgagnian Cataracts: Clinical Challenges and Surgical Outcomes in Advanced Lens Pathology https://news.medxy.ai/zh/pediatric-parotidectomy-experience/Medxy AIzh2026-11-02T05:02:02-08:00儿童腮腺切除术：三级中心十年经验带来的启示 https://news.medxy.ai/ja/pediatric-parotidectomy-review/Medxy AIja2026-11-02T05:01:42-08:00小児耳下腺切除の10年を振り返る：三次医療機関からの知見 https://news.medxy.ai/vi/parotid-surgery-children/Medxy AIvi2026-11-02T05:01:20-08:00Phẫu thuật tuyến mang tai ở trẻ em: Góc nhìn từ 10 năm kinh nghiệm tại một trung tâm tuyến cuối https://news.medxy.ai/pediatric-parotidectomy-insights-from-a-decade-at-a-tertiary-center/Medxy AIen2026-11-02T05:01:03-08:00Pediatric Parotidectomy: Insights from a Decade at a Tertiary Center https://news.medxy.ai/zh/pancreatic-vein-thrombosis/Medxy AIzh2026-11-02T05:00:26-08:00胰腺癌术后静脉切除与门静脉-肠系膜静脉血栓形成：发生率、时间分布及危险因素 https://news.medxy.ai/ja/portomesenteric-vein-thrombosis/Medxy AIja2026-11-02T05:00:06-08:00静脈再建を伴う膵癌手術後の門脈腸間膜静脈血栓症：発生率・発症時期・危険因子 https://news.medxy.ai/vi/portomesenteric-vein-thrombosis-2/Medxy AIvi2026-11-02T04:59:43-08:00Huyết khối tĩnh mạch portomesenteric sau phẫu thuật ung thư tụy có cắt bỏ tĩnh mạch: tỷ lệ mắc, thời điểm xuất hiện và các yếu tố nguy cơ https://news.medxy.ai/portomesenteric-venous-thrombosis-after-pancreatic-cancer-surgery-with-venous-resection-incidence-timing-and-risk-factors/Medxy AIen2026-11-02T04:59:23-08:00Portomesenteric Venous Thrombosis After Pancreatic Cancer Surgery with Venous Resection: Incidence, Timing, and Risk Factors https://news.medxy.ai/ja/gestational-diabetes-treatment-comparison/Medxy AIja2026-11-02T04:58:39-08:00妊娠糖尿病における経口血糖降下薬とインスリンの比較：SUGAR-DIPランダム化比較試験に基づく社会的費用効果分析 https://news.medxy.ai/vi/oral-medication-vs-insulin/Medxy AIvi2026-11-02T04:58:18-08:00Thuốc hạ đường huyết đường uống hay insulin cho đái tháo đường thai kỳ? Phân tích chi phí-hiệu quả xã hội từ thử nghiệm SUGAR-DIP https://news.medxy.ai/oral-antihyperglycemic-agents-versus-insulin-for-gestational-diabetes-mellitus-societal-cost-effectiveness-analysis-of-the-sugar-dip-randomized-controlled-trial/Medxy AIen2026-11-02T04:58:01-08:00Oral Antihyperglycemic Agents Versus Insulin for Gestational Diabetes Mellitus: Societal Cost-Effectiveness Analysis of the SUGAR-DIP Randomized Controlled Trial https://news.medxy.ai/zh/saroglitazar-primary-biliary-cholangitis/Medxy AIzh2026-11-02T04:57:25-08:00Saroglitazar在原发性胆汁性胆管炎中的应用：来自2b/3期自适应随机试验的启示 https://news.medxy.ai/ja/saroglitazar-primary-biliary-cholangitis-3/Medxy AIja2026-11-02T04:57:04-08:00原発性胆汁性胆管炎におけるSaroglitazar：第2b/3相適応的無作為化試験からの知見 https://news.medxy.ai/vi/saroglitazar-primary-biliary-cholangitis-2/Medxy AIvi2026-11-02T04:56:40-08:00Saroglitazar trong xơ đường mật nguyên phát: Những phát hiện từ thử nghiệm ngẫu nhiên thích ứng pha 2b/3 https://news.medxy.ai/zh/us-tia-management-trends/Medxy AIzh2026-11-02T04:55:30-08:00美国急诊科短暂性脑缺血发作管理新趋势：演变、挑战与启示 https://news.medxy.ai/ja/emergency-tia-care-trends/Medxy AIja2026-11-02T04:55:10-08:00米国における一過性脳虚血発作の救急外来対応の変化：動向、課題、示唆 https://news.medxy.ai/vi/transient-ischemic-attack/Medxy AIvi2026-11-02T04:54:50-08:00Cơn thiếu máu não thoáng qua tại khoa cấp cứu Hoa Kỳ: xu hướng, thách thức và ý nghĩa lâm sàng https://news.medxy.ai/evolving-emergency-department-approaches-to-transient-ischemic-attack-in-the-us-trends-challenges-and-implications/Medxy AIen2026-11-02T04:54:31-08:00Evolving Emergency Department Approaches to Transient Ischemic Attack in the US: Trends, Challenges, and Implications https://news.medxy.ai/zh/metyrapone-cardiovascular-benefits/Medxy AIzh2026-11-02T04:53:48-08:00甲吡酮治疗轻度自主性皮质醇分泌：心血管获益与机制启示 https://news.medxy.ai/ja/mild-autonomous-cortisol-secretion-metyrapone-treatment/Medxy AIja2026-11-02T04:53:28-08:00軽度自律性コルチゾール分泌に対するメチラポン治療：心血管への利益と作用機序の示唆 https://news.medxy.ai/vi/low-dose-metyrapone-cortisol-secretion/Medxy AIvi2026-11-02T04:53:04-08:00Điều trị Metyrapone trong Tiết Cortisol Tự Trị Nhẹ: Lợi ích Tim mạch và Những Hiểu biết Cơ chế https://news.medxy.ai/metyrapone-treatment-in-mild-autonomous-cortisol-secretion-cardiovascular-benefits-and-mechanistic-insights/Medxy AIen2026-11-02T04:52:45-08:00Metyrapone Treatment in Mild Autonomous Cortisol Secretion: Cardiovascular Benefits and Mechanistic Insights https://news.medxy.ai/zh/acadm-fatty-acid-oxidation/Medxy AIzh2026-11-02T04:52:04-08:00ACADM介导的脂肪酸β-氧化：动脉粥样硬化与腹主动脉瘤中的差异性脂质代谢通路